Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04447755 · OUTCOME

Number of Participants Who Experienced an Adverse Event (AE)

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) · Source last updated 2025-10-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to approximately 50 months

What was measured

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.

Analysis population: All participants who received at least one dose of study treatment were analyzed.

Groups in this outcome

Ewing Sarcoma

Participants with Ewing sarcoma received lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.

Rhabdomyosarcoma

Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

High Grade Glioma

Participants with high grade glioma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

Diffuse Midline Glioma

Participants with diffuse midline glioma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

Medulloblastoma

Participants with medulloblastoma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

Ependymoma

Participants with ependymoma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma

Participants with other solid tumors received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ewing Sarcoma9
Rhabdomyosarcoma17
High Grade Glioma8
Diffuse Midline Glioma9
Medulloblastoma9
Ependymoma9
Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma66

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ewing Sarcoma9Not reportedNot reportedNot reportedNot reported
Rhabdomyosarcoma17Not reportedNot reportedNot reportedNot reported
High Grade Glioma8Not reportedNot reportedNot reportedNot reported
Diffuse Midline Glioma9Not reportedNot reportedNot reportedNot reported
Medulloblastoma9Not reportedNot reportedNot reportedNot reported
Ependymoma8Not reportedNot reportedNot reportedNot reported
Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma66Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        17
      3. group Id
        OG002
        value
        8
      4. group Id
        OG003
        value
        9
      5. group Id
        OG004
        value
        9
      6. group Id
        OG005
        value
        8
      7. group Id
        OG006
        value
        66
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      17
    3. group Id
      OG002
      value
      8
    4. group Id
      OG003
      value
      9
    5. group Id
      OG004
      value
      9
    6. group Id
      OG005
      value
      9
    7. group Id
      OG006
      value
      66
    units
    Participants
description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.
groups
  1. description
    Participants with Ewing sarcoma received lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.
    id
    OG000
    title
    Ewing Sarcoma
  2. description
    Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
    id
    OG001
    title
    Rhabdomyosarcoma
  3. description
    Participants with high grade glioma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
    id
    OG002
    title
    High Grade Glioma
  4. description
    Participants with diffuse midline glioma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
    id
    OG003
    title
    Diffuse Midline Glioma
  5. description
    Participants with medulloblastoma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
    id
    OG004
    title
    Medulloblastoma
  6. description
    Participants with ependymoma received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
    id
    OG005
    title
    Ependymoma
  7. description
    Participants with other solid tumors received lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
    id
    OG006
    title
    Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma
param Type
NUMBER
population Description
All participants who received at least one dose of study treatment were analyzed.
reporting Status
POSTED
time Frame
Up to approximately 50 months
title
Number of Participants Who Experienced an Adverse Event (AE)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice